Aethlon Medical, Inc. (AEMD), a company developing therapies for cancer and infectious diseases, has priced a public offering of 5,000,000 shares of common stock or pre-funded warrants and accompanying warrants to purchase up to 5,000,000 shares at $0.90 per unit.
The warrants are exercisable immediately at $0.90 and expire five years from issuance. The offering is expected to close on or about September 5, 2025, subject to customary conditions.
Maxim Group LLC is serving as the exclusive placement agent. Gross proceeds are expected to total approximately $4.5 million before fees and expenses. Aethlon plans to use the net proceeds for general corporate purposes, including clinical trials, R&D, capital expenditures, and working capital.
The securities are being offered under a Form S-1 registration statement declared effective by the SEC on September 4, 2024. The offering will be made only through the accompanying prospectus available via the SEC's website or Maxim Group.
Thursday AEMD closed at $0.7341, down 45.62%, and traded after hours to close at $0.7799, up 6.24% on the NasdaqCM.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.